CN121800915A - 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体 - Google Patents

用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体

Info

Publication number
CN121800915A
CN121800915A CN202511495657.4A CN202511495657A CN121800915A CN 121800915 A CN121800915 A CN 121800915A CN 202511495657 A CN202511495657 A CN 202511495657A CN 121800915 A CN121800915 A CN 121800915A
Authority
CN
China
Prior art keywords
seq
binding polypeptide
binding
nos
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511495657.4A
Other languages
English (en)
Chinese (zh)
Inventor
金明
L·普拉蒂尔
D·雷泽克
D·塞尔科
T·特拉瓦林
D·沃尔什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
The Brigham and Women's Hospital Inc
Original Assignee
Sanofi Aventis France
The Brigham and Women's Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France, The Brigham and Women's Hospital Inc filed Critical Sanofi Aventis France
Publication of CN121800915A publication Critical patent/CN121800915A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202511495657.4A 2019-07-16 2020-07-15 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体 Pending CN121800915A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962874724P 2019-07-16 2019-07-16
US62/874,724 2019-07-16
PCT/US2020/042161 WO2021011673A2 (en) 2019-07-16 2020-07-15 Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease
CN202080063538.0A CN115175932B (zh) 2019-07-16 2020-07-15 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080063538.0A Division CN115175932B (zh) 2019-07-16 2020-07-15 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体

Publications (1)

Publication Number Publication Date
CN121800915A true CN121800915A (zh) 2026-04-07

Family

ID=71895293

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202511495657.4A Pending CN121800915A (zh) 2019-07-16 2020-07-15 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
CN202080063538.0A Active CN115175932B (zh) 2019-07-16 2020-07-15 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
CN202511495659.3A Pending CN121949538A (zh) 2019-07-16 2020-07-15 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202080063538.0A Active CN115175932B (zh) 2019-07-16 2020-07-15 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
CN202511495659.3A Pending CN121949538A (zh) 2019-07-16 2020-07-15 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体

Country Status (7)

Country Link
US (1) US12630615B2 (cg-RX-API-DMAC7.html)
EP (1) EP3999532A2 (cg-RX-API-DMAC7.html)
JP (1) JP7685985B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220034857A (cg-RX-API-DMAC7.html)
CN (3) CN121800915A (cg-RX-API-DMAC7.html)
CA (2) CA3313684A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021011673A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
WO2026082154A1 (en) * 2024-10-18 2026-04-23 Lepu Biopharma Co., Ltd. Anti-beta amyloid antibodies and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU5545596A (en) 1995-04-28 1996-11-18 Medtronic, Inc. Intraparenchymal infusion catheter system
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US5735814A (en) 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
JP2006508072A (ja) * 2002-10-01 2006-03-09 ノースウエスタン ユニバーシティ アミロイドベータ由来拡散性リガンド（ＡＤＤＬｓ）、ＡＤＤＬ代替物、ＡＤＤＬ結合性分子、およびそれらの使用
US20160213794A1 (en) * 2002-10-01 2016-07-28 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules and uses thereof
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PE20090329A1 (es) 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
HRP20150086T1 (xx) * 2007-06-12 2015-02-27 Ac Immune S.A. Humanizirana antitijela za beta amiloid
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
WO2011133919A1 (en) * 2010-04-22 2011-10-27 Janssen Alzheimer Immunotherapy Use of tau to monitor immunotherapy
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US9221902B2 (en) * 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
US20130115227A1 (en) * 2010-07-14 2013-05-09 Renee C. Gaspar Anti-addl monoclonal antibody and uses thereof
KR102308915B1 (ko) * 2012-10-15 2021-10-06 메디뮨 리미티드 아밀로이드 베타에 대한 항체

Also Published As

Publication number Publication date
CN115175932A (zh) 2022-10-11
US20230107034A1 (en) 2023-04-06
JP2022541459A (ja) 2022-09-26
KR20220034857A (ko) 2022-03-18
US12630615B2 (en) 2026-05-19
EP3999532A2 (en) 2022-05-25
WO2021011673A2 (en) 2021-01-21
CN121949538A (zh) 2026-05-01
CA3313684A1 (en) 2026-06-21
WO2021011673A3 (en) 2021-07-01
CA3147239A1 (en) 2021-01-21
JP7685985B2 (ja) 2025-05-30
CN115175932B (zh) 2025-10-31

Similar Documents

Publication Publication Date Title
JP7608404B2 (ja) シヌクレイノパチーの治療のための薬剤、使用および方法
AU2022252753B2 (en) ANTIBODIES TO a-SYNUCLEIN AND USES THEREOF
US11472882B2 (en) Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
JP7399880B2 (ja) ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体
TWI673287B (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
EP3160999B1 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
CN115175932B (zh) 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
AU2008334637B2 (en) Antigen binding proteins
JP7352973B2 (ja) 二重特異性抗体及びその使用
CA3046857A1 (en) Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
WO2017071625A1 (zh) 一种抗pd-1单克隆抗体、其药物组合物及其用途
TW201716436A (zh) 特異性針對過度磷酸化τ蛋白之抗體及其使用方法
AU2009245354A1 (en) Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
KR20160037173A (ko) 치료학적 융합 단백질
WO2018219327A1 (zh) 抗cd40抗体、其抗原结合片段及其医药用途
CN110461874B (zh) 抗gitr抗体、其抗原结合片段及其医药用途
US10513561B2 (en) Anti-MYL9 antibody
TW202144433A (zh) 抗體或其抗原結合片段、其製備方法及醫藥用途
CN119264263A (zh) 靶向pd-1和lag3的双特异性抗体及其用途
HK1206365B (en) Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination